Pfizer 2025 Guidance Signals Relief to Investors, UBS Says

MT Newswires Live

Dec 19, 2024

Pfizer's (PFE) initial 2025 guidance signals relief to investors as it highlights stabilizing business with improving margins, UBS said in a note emailed Wednesday.

Pfizer on Tuesday projected higher earnings for 2025 and revenue in line with this year's likely result as the pharmaceutical giant looks to continue "disciplined execution" and cost cuts.

Revenue for next year is pegged at $61 billion to $64 billion, matching Pfizer's 2024 guidance given in October, which was at the time raised by $1.5 billion at the midpoint. Pfizer reiterated the 2024 outlook on Tuesday.

The company said it sees adjusted earnings of $2.80 to $3 a share. For this year, Pfizer affirmed its guidance for adjusted EPS of $2.75 to $2.95.

UBS said it expects $2.96 in earnings on revenue of $63.4 billion for 2025.

The firm said upside to the company's stock could come from the data readout of the once-a-day version of Pfizer's weight-loss pill danuglipron and focus on key growth asset in 2025 such as Nurtec and Abrysvo.

UBS has a neutral rating on the stock with a price target of $31.

Price: 26.08, Change: -0.35, Percent Change: -1.34

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2492515375"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492515375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2492515375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 04:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492515375","market":"sh","top_or_hot":-1,"title":"Pfizer 2025 Guidance Signals Relief to Investors, UBS Says","media":"MT Newswires Live","content":"<html><body><p> Pfizer's (PFE) initial 2025 guidance signals relief to investors as it highlights stabilizing business with improving margins, UBS said in a note emailed Wednesday.</p><p>Pfizer on Tuesday projected higher earnings for 2025 and revenue in line with this year's likely result as the pharmaceutical giant looks to continue \"disciplined execution\" and cost cuts.</p><p>Revenue for next year is pegged at $61 billion to $64 billion, matching Pfizer's 2024 guidance given in October, which was at the time raised by $1.5 billion at the midpoint. Pfizer reiterated the 2024 outlook on Tuesday.</p><p>The company said it sees adjusted earnings of $2.80 to $3 a share. For this year, Pfizer affirmed its guidance for adjusted EPS of $2.75 to $2.95.</p><p>UBS said it expects $2.96 in earnings on revenue of $63.4 billion for 2025.</p><p>The firm said upside to the company's stock could come from the data readout of the once-a-day version of Pfizer's weight-loss pill danuglipron and focus on key growth asset in 2025 such as Nurtec and Abrysvo.</p><p>UBS has a neutral rating on the stock with a price target of $31.</p><p>Price: 26.08, Change: -0.35, Percent Change: -1.34</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer 2025 Guidance Signals Relief to Investors, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer 2025 Guidance Signals Relief to Investors, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-19 04:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Pfizer's (PFE) initial 2025 guidance signals relief to investors as it highlights stabilizing business with improving margins, UBS said in a note emailed Wednesday.</p><p>Pfizer on Tuesday projected higher earnings for 2025 and revenue in line with this year's likely result as the pharmaceutical giant looks to continue \"disciplined execution\" and cost cuts.</p><p>Revenue for next year is pegged at $61 billion to $64 billion, matching Pfizer's 2024 guidance given in October, which was at the time raised by $1.5 billion at the midpoint. Pfizer reiterated the 2024 outlook on Tuesday.</p><p>The company said it sees adjusted earnings of $2.80 to $3 a share. For this year, Pfizer affirmed its guidance for adjusted EPS of $2.75 to $2.95.</p><p>UBS said it expects $2.96 in earnings on revenue of $63.4 billion for 2025.</p><p>The firm said upside to the company's stock could come from the data readout of the once-a-day version of Pfizer's weight-loss pill danuglipron and focus on key growth asset in 2025 such as Nurtec and Abrysvo.</p><p>UBS has a neutral rating on the stock with a price target of $31.</p><p>Price: 26.08, Change: -0.35, Percent Change: -1.34</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999002232.USD","symbol_name":"Allianz Global High Payout USD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492515375","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492515375","pubTimestamp":1734552453,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pfizer's  initial 2025 guidance signals relief to investors as it highlights stabilizing business with improving margins, UBS said in a note emailed Wednesday.Pfizer on Tuesday projected higher earnings for 2025 and revenue in line with this year's likely result as the pharmaceutical giant looks to continue \"disciplined execution\" and cost cuts.Revenue for next year is pegged at $61 billion to $64 billion, matching Pfizer's 2024 guidance given in October, which was at the time raised by $1.5 billion at the midpoint. Pfizer reiterated the 2024 outlook on Tuesday.The company said it sees adjusted earnings of $2.80 to $3 a share. For this year, Pfizer affirmed its guidance for adjusted EPS of $2.75 to $2.95.UBS said it expects $2.96 in earnings on revenue of $63.4 billion for 2025.The firm said upside to the company's stock could come from the data readout of the once-a-day version of Pfizer's weight-loss pill danuglipron and focus on key growth asset in 2025 such as Nurtec and Abrysvo.UB","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4581":"高盛持仓","PFE":"辉瑞","ISBC":"投资者银行","BK4585":"ETF&股票定投概念","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4534":"瑞士信贷持仓","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","PFE.AU":"PANTERA MINERALS LTD","BK4533":"AQR资本管理(全球第二大对冲基金)","BK7095":"多种金属与采矿","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0058720904.USD":"联博国际健康护理基金A","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4588":"碎股","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4007":"制药","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4211":"区域性银行","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4599":"减肥药"},"translate_title":"瑞银表示，辉瑞2025年指引让投资者松了一口气","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1,"ISBC":1,"PFE.AU":1},"content_text":"Pfizer's (PFE) initial 2025 guidance signals relief to investors as it highlights stabilizing business with improving margins, UBS said in a note emailed Wednesday.Pfizer on Tuesday projected higher earnings for 2025 and revenue in line with this year's likely result as the pharmaceutical giant looks to continue \"disciplined execution\" and cost cuts.Revenue for next year is pegged at $61 billion to $64 billion, matching Pfizer's 2024 guidance given in October, which was at the time raised by $1.5 billion at the midpoint. Pfizer reiterated the 2024 outlook on Tuesday.The company said it sees adjusted earnings of $2.80 to $3 a share. For this year, Pfizer affirmed its guidance for adjusted EPS of $2.75 to $2.95.UBS said it expects $2.96 in earnings on revenue of $63.4 billion for 2025.The firm said upside to the company's stock could come from the data readout of the once-a-day version of Pfizer's weight-loss pill danuglipron and focus on key growth asset in 2025 such as Nurtec and Abrysvo.UBS has a neutral rating on the stock with a price target of $31.Price: 26.08, Change: -0.35, Percent Change: -1.34","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}